Findings

What do systematic reviews say?

26 questions · 26 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 11.5%GRADE not reported 0 · 0%Very low 2 · 7.7%Low 3 · 11.5%Moderate 18 · 69.2%High 0 · 0%

Summary of findings: Folic acid vs placebo

Stomatitis / mouth sores (incidence) · Patients receiving methotrexate for rheumatoid arthritis

Folic acid showed no clear difference in stomatitis / mouth sores (incidence) compared with placebo (moderate certainty).

1 finding from 1 review

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 0.9 [0.53, 1.54]
2 studies · 302 participants
Moderate

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

All‐cause mortality at 1 year · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus folinic acid (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.81 [0.55, 1.2]
1 study · 41 participants
Very low

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Serious adverse events · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Helath‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Overall response rate · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus oxaliplatin changes overall response rate compared with 5‐fluorouracil plus folinic acid (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 2.15 [0.64, 7.29]
1 study · 41 participants
Very low

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found